All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells.
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-WFY2112 | Anti-MDM2 (CBFYM-0323) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse | CBFYM-0323 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2113 | Anti-MDM2 (CBFYM-0419) h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse, Rat, Human | CBFYM-0419 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2114 | Anti-MDM2 (CBFYM-0613) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-0613 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2115 | Anti-MDM2 (CBFYM-1955) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1955 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2116 | Anti-MDM2 (CBFYM-1956) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1956 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2117 | Anti-MDM2 (CBFYM-1957) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1957 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2118 | Anti-MDM2 (CBFYM-1958) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1958 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2119 | Anti-MDM2 (CBFYM-1959) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1959 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2120 | Anti-MDM2 (CBFYM-1960) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1960 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2121 | Anti-MDM2 (CBFYM-1961) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1961 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2122 | Anti-MDM2 (CBFYM-1962) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse | CBFYM-1962 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2123 | Anti-MDM2 (CBFYM-1963) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse | CBFYM-1963 | Rabbit | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2124 | Anti-MDM2 (CBFYM-1964) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse, Rat | CBFYM-1964 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY2125 | Anti-MDM2 (CBFYM-1965) h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse | CBFYM-1965 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5371 | Anti-MDM2 (CBFYM-1958) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1958 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5372 | Anti-MDM2 (CBFYM-1959) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1959 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5373 | Anti-MDM2 (CBFYM-1960) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1960 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5374 | Anti-MDM2 (CBFYM-1961) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYM-1961 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5375 | Anti-MDM2 (CBFYM-1962) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Mouse | CBFYM-1962 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY5376 | Anti-MDM2 (CBFYM-1963) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Mouse | CBFYM-1963 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION